PMID- 24982366
OWN - NLM
STAT- MEDLINE
DCOM- 20140821
LR  - 20161125
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 34
IP  - 7
DP  - 2014 Jul
TI  - Immunohistochemical evaluation of CXCL12-CXCR4 axis and VEGFR3 expression in 
      primary urothelial cancer and its recurrence.
PG  - 3537-42
AB  - AIM: The aim of this study was to investigate the expression of CXC chemokine 
      ligand-12 (CXCL12), CXC chemokine receptor 4 CXCR4 and of vascular endothelial 
      growth factor receptor 3 (VEGFR3) in primary urothelial bladder carcinoma and 
      their recurrence in relation to grade and pT status. MATERIALS AND METHODS: 
      Immunohistochemistry was applied to 67 primary tumor (PC) sections and their 
      recurrenct tumors (RC). RESULTS: The expression of CXCL12 both in PC and in RC 
      was positively associated with tumor grade (p<0.0001 and p<0.0001, respectively) 
      and pT stage (p=0.001 and p=0.007, respectively). The expression of CXCR4 in both 
      PC and RC was also positively related to grade (p=0.001 and p<0.0001, 
      respectively) and pT stage (p=0.008 and p=0.005, respectively). We compared the 
      expression of CXCL12 and CXCR4 in PC related to RC and found that both were more 
      intense in RC than in PC (p<0.0001 and p<0.0001, respectively). In PC and in RC 
      there was no association between the expression of VEGFR3 with tumor grade and pT 
      stage. CONCLUSION: CXCL12 and CXCR4 expression was related to adverse prognostic 
      markers in urothelial bladder carcinoma through their association with grade and 
      pT stage both in PC and RC. The CXCL12-CXCR4 axis may influence the expression of 
      VEGFR3 in urothelial bladder carcinoma and promote tumor recurrence.
CI  - Copyright(c) 2014 International Institute of Anticancer Research (Dr. John G. 
      Delinassios), All rights reserved.
FAU - Batsi, Ourania
AU  - Batsi O
AD  - Department of Pathology, Syggros Venereal and Skin Disease Hospital Athens, 
      Athens, Greece rania.mpatsi@gmail.com.
FAU - Giannopoulou, Ioanna
AU  - Giannopoulou I
AD  - First Department of Pathology, School of Medicine, National and Kapodistrian 
      University of Athens, Athens, Greece.
FAU - Nesseris, Ioannis
AU  - Nesseris I
AD  - Department of Pathology, Syggros Venereal and Skin Disease Hospital Athens, 
      Athens, Greece.
FAU - Valavanis, Christos
AU  - Valavanis C
AD  - Department of Pathology Metaxa Cancer Hospital, Piraeus, Greece.
FAU - Gakiopoulou, Hariklia
AU  - Gakiopoulou H
AD  - First Department of Pathology, School of Medicine, National and Kapodistrian 
      University of Athens, Athens, Greece.
FAU - Patsouris, Efstratios S
AU  - Patsouris ES
AD  - First Department of Pathology, School of Medicine, National and Kapodistrian 
      University of Athens, Athens, Greece.
FAU - Arapandoni-Dadioti, Petroula
AU  - Arapandoni-Dadioti P
AD  - Department of Pathology Metaxa Cancer Hospital, Piraeus, Greece.
FAU - Lazaris, Andreas C
AU  - Lazaris AC
AD  - First Department of Pathology, School of Medicine, National and Kapodistrian 
      University of Athens, Athens, Greece.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (CXCL12 protein, human)
RN  - 0 (CXCR4 protein, human)
RN  - 0 (Chemokine CXCL12)
RN  - 0 (Receptors, CXCR4)
RN  - EC 2.7.10.1 (FLT4 protein, human)
RN  - EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-3)
SB  - IM
MH  - Chemokine CXCL12/*biosynthesis
MH  - Humans
MH  - Immunohistochemistry
MH  - Neoplasm Grading
MH  - Neoplasm Recurrence, Local/metabolism
MH  - Neoplasm Staging
MH  - Receptors, CXCR4/*biosynthesis
MH  - Urinary Bladder Neoplasms/*metabolism
MH  - Vascular Endothelial Growth Factor Receptor-3/*biosynthesis
OTO - NOTNLM
OT  - CXCL12
OT  - CXCR4
OT  - VEGFR-3
OT  - recurrence
OT  - urothelial cancer
EDAT- 2014/07/02 06:00
MHDA- 2014/08/22 06:00
CRDT- 2014/07/02 06:00
PHST- 2014/07/02 06:00 [entrez]
PHST- 2014/07/02 06:00 [pubmed]
PHST- 2014/08/22 06:00 [medline]
AID - 34/7/3537 [pii]
PST - ppublish
SO  - Anticancer Res. 2014 Jul;34(7):3537-42.